Sarepta Therapeutic (SRPT) PT Raised to $102 at Baird
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Updated - September 19, 2016 12:23 PM EDT)
Baird reiterated an Outperform rating and raised its price target on Sarepta Therapeutic (NASDAQ: SRPT) to $102.00 (from $23.00) following FDA approval of eteplirsen.
Analyst Brian Skorney commented, "After months of delays, requests for additional data, and a slew of other DMD rejections, the FDA handed Sarepta a victory this morning. Eteplirsen, branded as EXONDYS 51, has been approved under the accelerated pathway, with a broad label. As a result of the approval and receipt of a potentially lucrative priority review voucher, we are increasing our price target to $102, which now takes into account increased probabilities of commercial expansion into other exons."
Shares of Sarepta Therapeutic closed at $28.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird Reiterates Bullish View on Sarepta (SRPT) as ESSENCE Starts Dosing
- Leerink Partners Says Exelixis (EXEL) Sell-Off on ESMO Abstracts 'Overdone'
- Pacific Crest Cuts Fitbit (FIT) to 'Underperform'; Charge 2 Off to Slow Start, Says Analyst
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Hot Comments, Trader Talk
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!